Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Dimed Distribuidora de Medicamentos's Revenue for the
three
months ended in Mar. 2026 was R$1,450 Mil. Dimed Distribuidora de Medicamentos's average Accounts Receivable for the
three
months ended in Mar. 2026 was R$558 Mil.
Hence, Dimed Distribuidora de Medicamentos's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.60.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Dimed Distribuidora de Medicamentos Receivables Turnover Related Terms
Dimed Distribuidora de Medicamentos Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos Receivables Turnover Chart
BSP:PNVL3 vs LLY, JNJ, ABBV: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimed Distribuidora de Medicamentos Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Dimed Distribuidora de Medicamentos's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a Receivables Turnover of 2.60 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Dimed Distribuidora de Medicamentos and its competitors. According to the industry distribution chart, Dimed Distribuidora de Medicamentos ranks #105 out of 950 companies in the Drug Manufacturers industry, placing it in the top 11.1%.
Is Dimed Distribuidora de Medicamentos' Receivables Turnover too high?
Dimed Distribuidora de Medicamentos' current Receivables Turnover is 2.60. The Drug Manufacturers industry median Receivables Turnover is 5.07. Dimed Distribuidora de Medicamentos' value of 2.60 is 48.7% below this industry median. Based on the distribution chart, Dimed Distribuidora de Medicamentos ranks #105 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' Receivables Turnover compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dimed Distribuidora de Medicamentos ranks #105 out of 950 companies for Receivables Turnover. This places Dimed Distribuidora de Medicamentos in the top 11% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Dimed Distribuidora de Medicamentos' value of 2.60 is 48.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dimed Distribuidora de Medicamentos's current Receivables Turnover of 2.60 is 48.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Dimed Distribuidora de Medicamentos and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimed Distribuidora de Medicamentos's current Receivables Turnover is 2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.76, compared to a current price of R$11.51 — trading 16.4% below its estimated fair value. The current Receivables Turnover is 2.60 and 48.7% below the Drug Manufacturers industry median of 5.07. Dimed Distribuidora de Medicamentos' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current Receivables Turnover is 2.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued.
The current stock price of R$11.51 is trading 16.4% below its estimated GF Value™ of R$13.76.
GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.
Key valuation signals for BSP:PNVL3:
Receivables Turnover: 2.60
GF Value™: R$13.76 vs. price of R$11.51 (16.4% below fair value)
Industry Position: 48.7% below the Drug Manufacturers median (#105 of 950)
No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dimed Distribuidora de Medicamentos Business Description
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
89GF Score
Get the complete analysis for BSP:PNVL3
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PNVL3 has been successfully added to your 
